64 results about "Anti-Müllerian hormone" patented technology

The invention discloses an anti-mullerian hormone chemiluminescence immunoassay kit and a preparation method and application thereof. The anti-mullerian hormone chemiluminescence immunoassay kit comprises a solid-phase carrier enveloped by an anti-mullerian hormone monoclonal antibody, and an anti-mullerian hormone monoclonal antibody marked by a chemiluminescence marker. The anti-mullerian hormone chemiluminescence immunoassay kit can complete the assay of anti-mullerian hormone by taking a full-automatic chemiluminescence immunoassay analyzer as an assay tool. Through experiments, the assay sensitivity of the anti-mullerian hormone chemiluminescence immunoassay kit can reach 0.01ng / mL, and is improved by at last ten times compared with the traditional anti-mullerian hormone assay method, and the assay precision of the anti-mullerian hormone chemiluminescence immunoassay kit is higher.

The present invention discloses compositions and methods to measure an amount of Anti-Mullerian Hormone (AMH) in a sample, including a mammalian sample such as a primate, rodent, equine, or bovine sample. The compositions and methods herein also provide antibodies that bind to epitopes on AMH that are stable to proteolysis of AMH.

The present invention relates to a system for assessing ovarian reserve functions in subjects. The system for assessing the ovarian reserve functions of the subjects comprises a data acquisition module used for obtaining data of a subject's age, an anti-Mullerian hormone (AMH) level, a follicle stimulating hormone (FSH) level and antral follicle counting (AFC); and a module for calculating the ovarian reserve functions used for calculating information obtained in the data acquisition module to calculate a probability (p) of subject's ovarian hyporesponsiveness. Further, a relationship betweenthe predicted ovarian hyporesponsiveness probability and a medicine dose of an ovulation-promoting medicine is predicted to divide populations into four groups in order to group closes ovarian responsiveness into one group.

The invention relates to a fluorescence immunochromatographic detecting method for anti-mullerian hormone and a kit thereof. The method includes steps of preparing a probe fixing pad, preparing an immunochromatographic test paper strip, preparing a sample diluting liquid and detecting a sample, wherein the probe fixing pad is prepared by mixing anti-mullerian hormone monoclonal antibody fluorescence latex microparticles and goat anti-rabbit IgG fluorescence latex microparticles, diluting with a gold diluting liquid and spraying glass fibers with the diluted solution. A detection line is covered with an anti-mullerian hormone monoclonal antibody, and a control line is covered with goat anti-rabbit IgG so as to prepare the immunochromatographic test paper strip. The kit comprises an immunochromatographic detecting card. The immunochromatographic detecting card comprises a PVC liner plate, a sample pad, the probe fixing pad, a nitrocellulose membrane and water absorbing paper. The probe fixing pad is prepared by mixing the anti-mullerian hormone monoclonal antibody fluorescence latex microparticles and the goat anti-rabbit IgG fluorescence latex microparticles and drying. The method and the kit are advantaged by high detection sensitivity, high accuracy, simple operation and a low cost.

The present invention discloses compositions and methods to measure an amount of Anti-Mullerian Hormone (AMH) in a sample, including a mammalian sample such as a primate, rodent, equine, or bovine sample. The compositions and methods herein also provide antibodies that bind to epitopes on AMH that are stable to proteolysis of AMH.

The present invention provides methods, kits, compositions, and devices for detecting Anti-Mullerian hormone (AMH) in whole blood samples. In certain embodiments, the methods, kits, compositions, and devices employ immunoassays that generate a colorimetric or fluorescent signal (e.g., using antibodies conjugated to gold nanoparticles or fluorescent particles) where the signal generated is proportional to the approximate concentration of AMH in a whole blood sample. In particular embodiments, the present invention provides quantitative or semi-quantitative lateral flow immunoassay devices and kits for detecting AMH at home (e.g., in order for women to estimate their ovarian age or diagnose polycystic ovarian syndrome).

The invention relates to a molecular genetic marker associated with egg-laying traits of ducks and application of the molecular genetic marker, belongs to the field of poultry breeding, and particularly relates to application of a G575A site of an AMH (anti-Mullerian hormone) gene, associated with egg-laying traits of ducks, serving as a molecular genetic marker in duck production performance research. A specific DNA segment is obtained from the AMH gene to serve as a molecular marker associated with the egg-laying traits of the ducks, one G575-A575 basic group in a sequence of the molecular marker mutates, the mutation site is significantly associated with the 43-week-old egg production and the 72-week-old egg production of the ducks (P smaller than 0.05), and by performing PCR (polymerase chain reaction) amplification and performing sequencing-based typing on a PCR product, a GG genotype is selected as an laying duck. A detection method provided by the invention is significant in effect, is simple and quick, and is not influenced by an external environment.

The invention relates to a system for predicting the number of oocytes obtained during ovarian stimulation of an object receiving a standard GnRH antagonist solution for ovulation induction. The system comprises a data acquisition module used for obtaining data of the anti-mullerian hormone (AMH) level, basal follicle stimulating hormone (FSH) level and antrum follicle count (AFC) of the object and a module used for predicting the number of the oocytes obtained during the ovarian stimulation and calculating the information obtained in the data acquisition module to calculate the number of theoocytes (NROs) obtained by the object.

The invention discloses a test strip for quantitatively detecting anti-mullerian hormone, a preparation method thereof and a determination method for the concentration of the anti-mullerian hormone, and belongs to the technical field of biology. The test strip comprises a base plate. A sample absorption pad, a labeled antibody pad, a coating film and a water absorption pad are sequentially attached to the base plate. The test strip has the advantages of being accurate in detection result, convenient to use and low in cost.

The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.

The invention discloses a human anti-mullerian hormone gold immunochromatographic detection kit and a method thereof. The detection kit comprises a reagent clamping shell, a baseboard arranged inside the reagent clamping shell, a sample pad disposed at one end of the baseboard, a colloidal gold pad with one end pressing against the sample pad, a detection pad with one end pressing against the other end of the colloidal gold pad and an absorption pad contacted with the other end of the detection pad, wherein the colloidal gold pad contains colloidal gold nanoparticles and a first antibody bound to mouse-anti-human AMH, and a detection line and a quality control line which are misaligned are distributed on the detection pad. The detection line contains a second mouse-anti-human AMH antibody, and the quality control line contains a third anti-first-antibody antibody. According to the invention, concentration of AMH in female serum can be rapidly and instantly detected so as to be used in evaluating activity and storing capacity of ovums in a woman's ovary. The detection kit is accurate and fast and has high sensitivity. No professionals are needed to operate the kit. In addition, the kit is low-cost and is convenient to promote and use.

The invention discloses a preparation method of magnetic particle chemiluminescence detection kit for testing human body anti-mullerian hormone content. The kit contains anti-mullerian hormone R1 reagent, anti-mullerian hormone R2 reagent, a magnetic separation reagent, standard product liquid series and chemiluminescence substrate solution; the anti-mullerian hormone R1 reagent is anti-mullerianhormone monoclonal antibody diluent marked by fluorescein isothiocyanate, the anti-mullerian hormone R2 reagent is anti-mullerian hormone antibody diluent marked by alkaline phosphatase, the magneticseparation reagent is magnetic particle diluent coated by anti-fluorescein isothiocyanate monoclonal antibody, the anti-mullerian hormone standard product liquid is formed by synthesized anti-mullerian hormone and buffer liquid, and the chemiluminescence substrate solution is Tris-HCL buffer liquid which is catalyzed by alkaline phosphatase and contains dioxane. The method greatly improves the signal intensity and sensitivity of immunoreaction, can enable low-content substances to generate a strong chemiluminescence signal when performing immune binding, so as to provide a more accurate, accurate, convenient, rapid and simple method for detection of anti-mullerian hormone.

The present invention relates to a system for predicting the probability of poor ovarian response of a subject under an antagonist regimen, and a system for guiding the selection of a gonadotropin starting medication dose. The system for predicting the probability of poor ovarian response includes: a data acquisition module for acquiring the age, the anti-Mullerian hormone (AMH) level, the follicle stimulating hormone (FSH) level, the antralfollicle count (AFC) data of the subject; and a module for calculating the probability of poor ovarian response, which is used for calculating the information obtained in the data acquisition module to calculate the probability of poor ovarian response of the subject, and giving a starting dose recommendation for exogenous gonadotropin (Gn) based on thepredicted probability of poor ovarian response.

The invention provides an anti-mullerian hormone (AMH) antibody and a preparation method thereof. The AMH antibody is prepared by selecting amino acid sequences of an appropriate position and length as an immunity antigen to immunize an animal and further by optimizing the antibody. The anti-AMH antibody provided by the invention cannot be combined with unstable amino acid sequences between the 26th site and the 59th site in the full-length AMH, so that the immunity reaction intensity is improved, and the detection sensitivity is greatly improved.

The invention discloses an effect study method of melatonin in prediction of ovarian reserve and IVF-ET (in-vitro fertilization and embryo transfer) outcome. The method includes: collecting basic clinical data of 61 females, and dividing the 61 females into three groups, namely a poor ovarian response group, a normal ovarian response group and a high ovarian response group mainly through age, retrieved oocyte number and anti-mullerian hormone value according to the stimulus response of the ovaries; collecting follicular fluid of the 61 females, adopting melatonin radioimmunoassay to determine melatonin concentration in the follicular fluid of the 61 females, and analyzing the levels of the melatonin concentration and other clinical data in the poor ovarian response group, the normal ovarian response group and the high ovarian response group; analyzing the levels of relevant data of in-vitro fertilization outcome in the poor ovarian response group, the normal ovarian response group and the high ovarian response group, and verifying relevance of the melatonin concentration and IVF-ET outcome; verifying relevance of the melatonin level and ovarian reserve. Through detection of melatonin concentration in the follicular fluid, ovarian reserve and IVF-ET outcome are predicted.

The invention relates to a test strip, a kit and a method for detecting AMH (anti-mullerian hormone) with TRFIA (time-resolved fluorescence immunoassay). The test strip comprises a PVC bottom plate, awhole blood filter pad, an antibody carrying membrane and absorbent paper. The kit comprises the test strip for detecting the AMH with the TRFIA, a sample buffer solution and an ID card containing anAMH standard curve. The kit can meet the requirement of single-person and small-batch detection of AMH and has the advantages of high sensitivity, high specificity, small blood amount, short detection time, operation convenience and detection result accuracy and reliability.

Disclosed are compositions and methods for detecting and quantifying human anti-Mtillerian hormone (AMH) in biological samples. In particular, the invention provides novel methods of measuring different forms of AMH in a biological sample, such as human plasma The anti-AMH antibody compositions disclosed herein enable reproducible measurement and quantitation of AMH, including dimeric forms of the AMH protein and fragments thereof. The antibody compositions disclosed herein find particular utility as diagnostic tools for single epitope sandwich-based AMH assays, which can be used to diagnose a variety of medical conditions.

The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about one month, and evaluating a second anti-Müllerian hormone level of the female, wherein the second anti-Müllerian hormone level is greater than the first anti-Müllerian hormone level.

The invention discloses a traditional Chinese medicine composition for treating decrease of ovarian reserve functions. The traditional Chinese medicine composition is prepared from effective components and medicine excipients. The effective components comprise, by weight, 5-30 parts of radix rehmanniae preparata, 6-30 parts of fructus lycii, 9-30 parts of caulis spatholobi, 9-35 parts of herba epimedii, 5-30 parts of semen cuscutae, 5-30 parts of herba cistanches, 3-30 parts of rhizoma cyperi and 3-15 parts of fructus crataegi. The traditional Chinese medicine composition has the advantages that menstrual amount decrease symptoms related to the decrease of the ovarian reserve functions can be obviously relieved by the traditional Chinese medicine composition, and effective up-regulation effects can be realized for related hormone AMH (anti-mullerian hormone) which can reflect the decrease of the ovarian reserve functions; MRS scores and traditional Chinese medicine symptom scores which can reflect the life quality of patients can be improved by the traditional Chinese medicine composition; effects of the traditional Chinese medicine composition for improving the decrease of the ovarian reserve functions are possibly relevant to improvement of ovarian blood supply and reduction of artery blood resistance indexes; the traditional Chinese medicine composition is free of obvious side effects when used within short time.

The invention discloses a flow detection reagent for human anti-Mullerian hormone, a preparation method of the flow detection reagent and application. The reagent is characterized by comprising an antibody Ab1-microsphere conjugate used for detecting the content of anti-Mullerian hormone in human serum or blood, and an antibody Ab2-fluorescent molecular marker. The preparation method comprises the following steps: preparing and pairing human anti-Mullerian hormone monoclonal antibodies, coupling between the human anti-Mullerian hormone monoclonal antibodies and carrier microspheres, and fluorescent molecular marking of the monoclonal antibodies. The flow detection reagent has the advantages that the content of AMH is directly judged according to fluorescence values, an experimental result can be obtained only by adding a blood sample into the reagent, the experimental operation steps during detection are simplified, moreover, high-throughput and multi-sample continuous detection can be realized through an automatic sample adding system, the detection efficiency is greatly improved, and the detection sensitivity can reach 0.01ng / ml.

The invention relates to the field of antigen detection, in particular to a mullerian hormone determination kit for marking a luminescent indicator based on a reduction method. The kit comprises a solid-phase support and an AMH (Anti-mullerian hormone) capturing probe, wherein the solid-phase support is coated with an AMH first antibody; and the AMH capturing probe is an AMH second antibody markedwith a chemiluminescence signal strength indicator, wherein a method for marking the chemiluminescence signal strength indicator with the AMH second antibody comprises the following steps: cutting off a disulfide bond of the AMH second antibody with a reducing agent to make sulfhydryl group exposed, and then marking the chemiluminescence signal strength indicator on the AMH second antibody through a functional group capable of being connected with the sulfhydryl group. The kit, when used for detecting AMH, has the advantages of good stability, high sensitivity and wide linear range.

The invention relates to a human anti-Mullerian hormone (AMH) antibody and application thereof. Various antibodies are prepared and subjected to pairing screening, and an antibody combination is obtained, wherein the sensitivity and specificity of the antibody combination both can meet demands.

This invention relates to non-surgical assays that can be used to determine whether an animal that has a non-postpartum anestrous period of three months or greater, such as a dog or a cat, has been spayed. In particular, the present invention relates to devices, kits and methods that allow correlation of levels of Anti-Müllerian Hormone with the state of being spayed.

Method of early detection of risk of infertility and ovarian aging in and treatment of a human female who has not experienced infertility and is not otherwise indicated to have premature ovarian aging. A number of CGG repeats on each allele of the isolated FMR1 gene is measured by using an assay, and a testing regimen is performed only when the determined number of CGG repeats on one of the FMR1 gene alleles is less than 26. The testing regimen includes periodically measuring serum level of a hormone related to fertility, such as Anti-Müllerian Hormone, Follicle Stimulating Hormone and / or estradiol over a period of about three to eight years and, after each measurement, determining if the measured serum level is less than a set confidence interval for a human female of the same age of the female. If so, the human female is treated for premature ovarian aging.

The invention discloses a preparation method for an anti-mullerian hormone optical excitated chemiluminescent detection kit. The preparation method comprises the following steps: (1) preparing a luminescent reagent buffer solution; (2) preparing anti-AMH antibody coupled luminescent microparticles; (3) preparing a biotin labeled anti-AMH antibody; (4) preparing avidin labeled light-sensing microparticles; and (5) preparing an AMH calibrated product. The invention also discloses the anti-mullerian hormone optical excitated chemiluminescent detection kit prepared by the preparation method for the anti-mullerian hormone optical excitated chemiluminescent detection kit and an application method of the anti-mullerian hormone optical excitated chemiluminescent detection kit. By way of optical excitated chemiluminescence, that is chemiluminescence by means of singlet state oxygen transfer action between the light sensing microparticles and luminescent microparticles, the two microparticles are combined and luminescent, so that the detection specificity is improved. A luminescent material wrapped in the luminescent microparticles is unlikely to be interfered by the environment and has highspecificity and stability.

The invention discloses a preparation method of a human anti-mullerian hormone AMH homogeneous detection kit, and the method is as follows: a component comprising a receptor and a first binding unit bound to the receptor is prepared, the receptor can be reacted with singlet oxygen to generate a detectable signal, the first binding unit is capable of binding to the first epitope of anti-mullerian hormone AMH; a second component comprising a first label and a second binding unit bound to the first label is prepared, the second binding unit is capable of binding to the second epitope of the AMH,the first epitope and the second epitope of the AMH are epitopes with different binding properties or epitopes with a same binding property at different positions; and a third component comprising a donor and a first label specific binder bound to the donor is prepared, and the donor is capable of generating the singlet oxygen in an excited state. The kit prepared by the method can efficiently detect the AMH.

The invention relates to an anti-Mullerian hormone quantitative measurement reagent and method based on a rare earth nanometer up-converting phosphor method. UCP particles in which the up-converting phosphor method is adopted are used as a biomarker, and an anti-AMH antibody is specifically marked. Through the adoption of the anti-Mullerian hormone quantitative measurement reagent and method based on the up-converting phosphor method, the content of AMH in a measured sample can be quickly, simply, quantitatively and accurately measured, and a detection basis is provided for evaluation of the female ovarian reserve function.

The invention discloses an anti-mullerian hormone AMH gene for epinephelus lanceolatus. A nucleotide sequence of the anti-mullerian hormone AMH gene is shown as SEQ ID NO:1. The invention also discloses protein encoded by the gene, a preparation method for producing anti-mullerian hormone AMH recombinant protein by adopting the anti-mullerian hormone AMH gene as a target gene, and a polyclonal antibody prepared by adopting the anti-mullerian hormone AMH recombinant protein obtained by the method as antigen to immunize animals. The invention further discloses application of anti-mullerian hormone AMH recombinant plasmid to preparation of an inducer in a sex-reversal process of the epinephelus lanceolatus and application of the polyclonal antibody to preparation of detecting agents for different developmental periods of the epinephelus lanceolatus.

The invention relates to the field of immunoassay, and in particular to a human anti-Mullerian hormone assay reagent kit with high sensitivity and the wide detection range. The human anti-Mullerian hormone (AMH) assay reagent kit comprises a reagent 1, a reagent 2, and human AMH calibrators of different gradient concentrations, wherein the reagent 2 comprises carboxylate latex microspheres labeledonly with human AMH monoclonal antibodies and carboxylate latex microspheres labeled only with human AMH polyclonal antibodies, and the average particle diameter of the carboxylate latex microsphereslabeled only with the human AMH monoclonal antibodies is greater than that of the carboxylate latex microspheres labeled only with the human AMH polyclonal antibodies. According to the human AMH assay reagent kit, detection of a single sample can be finished within 10 minutes, and indexes such as precision, accuracy and interference resistance are excellent.

The invention relates to an anti-Müllerian hormone (AMH) detection device and method, comprising a plurality of detection boxes and a plurality of reagent bottles, the detection boxes are respectively used for sample detection, blank zero adjustment detection, and comparative detection, and the reagent bottles are respectively filled with There are different concentrations of contrast reagents. The detection box includes a shell, a sample pad, a nitrocellulose membrane, and a water-absorbing pad. The shell is provided with a nitrocellulose membrane. The housing is provided with a sample hole at the position of the sample pad, and an observation hole is provided at the position of the nitrocellulose membrane, and the nitrocellulose membrane is provided with a detection line and a quality inspection line. The invention is convenient to use, can be detected by a single person, can ensure accurate detection results, and is beneficial to interpretation.